|
Status |
Public on May 22, 2012 |
Title |
Fib_D_VI_breast_P2_43 |
Sample type |
genomic |
|
|
Source name |
human dermal fibroblasts - passage 2
|
Organism |
Homo sapiens |
Characteristics |
cell type: human dermal fibroblasts from breast passage: P2 age: 43 gender: female
|
Treatment protocol |
Cells were harvested by trypsination after early or late passages.
|
Extracted molecule |
genomic DNA |
Extraction protocol |
Genomic DNA of approximately 10(6) dermal fibroblasts was isolated using the QIAGEN DNA Blood Midi-Kit. DNA quality was assessed with a NanoDrop ND-1000 spectrometer (NanoDrop Technologies, Wilmigton, Del) and average fragment length was assessed by gel electrophoresis.
|
Label |
biotin
|
Label protocol |
Genomic DNA (600 ng) from each sample was bisulfite converted using the EpiTect Bisulfite Kit (Qiagen, Hilden, Germany). This step leads to the deamination of non-methylated cytosines to uracils, while methylated cytosines are refractory to the effects of bisulfite and remain cytosine. After bisulfate conversion each sample was whole genome amplified and enzymatically fragmented.
|
|
|
Hybridization protocol |
The HumanMethylation27 BeadChip (Illumina, San Diego, USA) was hybridized with 200ng DNA.
|
Scan protocol |
The HumanMethylation27 BeadChip (Illumina, San Diego, USA) was scanned using the BeadArray Reader.
|
Data processing |
Initial data analysis was performed with the BeadStudio Methylation software from Illumina (ie, BeadStudio Methylation Analysis Module 3.2.0). Raw data were background normalized.
|
|
|
Submission date |
Jun 01, 2011 |
Last update date |
May 22, 2012 |
Contact name |
Wolfgang Wagner |
E-mail(s) |
wwagner@ukaachen.de
|
Phone |
+49 241 8088611
|
Organization name |
RWTH Aachen University
|
Department |
Helmholtz Institute for Biomedical Engineering
|
Lab |
Stem Cell Biology and Cellular Engineering
|
Street address |
Pauwelsstrasse 20
|
City |
Aachen |
ZIP/Postal code |
52074 |
Country |
Germany |
|
|
Platform ID |
GPL8490 |
Series (1) |
GSE29661 |
Cellular aging can be monitored by DNA-methylation changes at specific CpG sites |
|